Fate Therapeutics (FATE) Misses Q1 EPS by 5c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance